» Articles » PMID: 35884405

Stromal Co-Cultivation for Modeling Breast Cancer Dormancy in the Bone Marrow

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Jul 27
PMID 35884405
Authors
Affiliations
Soon will be listed here.
Abstract

Cancers metastasize to the bone marrow before primary tumors can be detected. Bone marrow micrometastases are resistant to therapy, and while they are able to remain dormant for decades, they recur steadily and result in incurable metastatic disease. The bone marrow microenvironment maintains the dormancy and chemoresistance of micrometastases through interactions with multiple cell types and through structural and soluble factors. Modeling dormancy in vitro can identify the mechanisms of these interactions. Modeling also identifies mechanisms able to disrupt these interactions or define novel interactions that promote the reawakening of dormant cells. The in vitro modeling of the interactions of cancer cells with various bone marrow elements can generate hypotheses on the mechanisms that control dormancy, treatment resistance and reawakening in vivo. These hypotheses can guide in vivo murine experiments that have high probabilities of succeeding in order to verify in vitro findings while minimizing the use of animals in experiments. This review outlines the existing data on predominant stromal cell types and their use in 2D co-cultures with cancer cells.

Citing Articles

Bone Marrow Stroma Co-cultivation Model of Breast Cancer Dormancy.

Wieder R Methods Mol Biol. 2024; 2811:55-67.

PMID: 39037649 DOI: 10.1007/978-1-0716-3882-8_4.


Outlook and opportunities for engineered environments of breast cancer dormancy.

Richbourg N, Irakoze N, Kim H, Peyton S Sci Adv. 2024; 10(10):eadl0165.

PMID: 38457510 PMC: 10923521. DOI: 10.1126/sciadv.adl0165.


Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients.

Khorsandi D, Yang J, Foster S, Khosravi S, Kouchehbaghi N, Zarei F Adv Healthc Mater. 2024; 13(21):e2302331.

PMID: 38359321 PMC: 11324859. DOI: 10.1002/adhm.202302331.


Awakening of Dormant Breast Cancer Cells in the Bone Marrow.

Wieder R Cancers (Basel). 2023; 15(11).

PMID: 37296983 PMC: 10252003. DOI: 10.3390/cancers15113021.


Fibroblasts as Turned Agents in Cancer Progression.

Wieder R Cancers (Basel). 2023; 15(7).

PMID: 37046676 PMC: 10093070. DOI: 10.3390/cancers15072014.

References
1.
Mercatali L, La Manna F, Miserocchi G, Liverani C, De Vita A, Spadazzi C . Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. Int J Mol Sci. 2017; 18(8). PMC: 5578045. DOI: 10.3390/ijms18081655. View

2.
Kim E, Nam S, Song H, Lee S, Kim K, Lim H . CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity. Oncogene. 2021; 40(18):3245-3259. DOI: 10.1038/s41388-021-01758-w. View

3.
Risson E, Nobre A, Maguer-Satta V, Aguirre-Ghiso J . The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer. 2021; 1(7):672-680. PMC: 7929485. DOI: 10.1038/s43018-020-0088-5. View

4.
Liu Z, Wang H, He J, Yuan X, Sun W . Rictor ablation in BMSCs inhibits bone metastasis of TM40D cells by attenuating osteolytic destruction and CAF formation. Int J Biol Sci. 2019; 15(11):2448-2460. PMC: 6775318. DOI: 10.7150/ijbs.37241. View

5.
Lee Y, Jung W, Koo J . Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells. Breast Cancer Res Treat. 2015; 153(2):323-35. DOI: 10.1007/s10549-015-3550-9. View